WilmerHale Partner Rachael Kent will be on a panel titled “Why International Arbitration for Life Sciences Disputes?”
The life sciences industry—pharmaceuticals, medical devices, diagnostics, vaccines and related businesses—is huge, growing and global, with international licensing, sales contracts, research and development agreements and joint ventures.
Each of these international ventures can lead to disputes, and well-positioned life sciences companies prefer international arbitration to litigation as the practical way to achieve confidential, widely enforceable judgments in a neutral setting.
Listen in as a distinguished panel of speakers explain why international arbitration is the preferred dispute resolution mechanism for life sciences disputes, before they take a deeper dive into some of the complex issues that can arise in such disputes. Join the panelist for a reception following the event.